Corporate News     24-Jul-23
AstraZeneca Pharma receives DCGI approves to import pharmaceutical formulation for Dapagliflozin Tablets
AstraZeneca Pharma India has received Permission to Import Pharmaceutical Formulations of New Drug for Sale or for Distribution in Form CT-20 (Marketing Authorisation – Additional Indication) from the Drugs Controller General of India for Dapagliflozin Tablets 10 mg.

Dapagliflozin Tablets 10mg is indicated for the treatment of heart failure in adults.

The receipt of this permission paves way for the launch of Dapagliflozin Tablets 10mg in India for the specified indication, subject to the receipt of related statutory approvals and licenses.

Previous News
  Astrazeneca Pharma India standalone net profit rises 96.78% in the June 2022 quarter
 ( Results - Announcements 08-Aug-22   14:55 )
  Volumes spurt at Astrazeneca Pharma India Ltd counter
 ( Hot Pursuit - 24-Sep-24   14:30 )
  Astrazeneca Pharma India Ltd leads gainers in 'A' group
 ( Hot Pursuit - 24-Sep-24   12:00 )
  Astrazeneca Pharma India to announce Quarterly Result
 ( Corporate News - 01-Nov-22   10:34 )
  Astrazeneca Pharma rises on planning to launch Enhertu
 ( Hot Pursuit - 21-Dec-23   10:01 )
  Volumes jump at Astrazeneca Pharma India Ltd counter
 ( Hot Pursuit - 12-Sep-22   14:30 )
  Volumes spurt at SKF India Ltd counter
 ( Hot Pursuit - 24-Sep-24   11:00 )
  AstraZeneca Pharma slumps after Q3 PAT slides 46% YoY to Rs 16 cr
 ( Hot Pursuit - 09-Feb-24   10:32 )
  Astrazeneca Pharma India standalone net profit rises 184.76% in the March 2021 quarter
 ( Results - Announcements 25-May-21   17:28 )
  Astrazeneca Pharma India standalone net profit rises 57.94% in the September 2019 quarter
 ( Results - Announcements 11-Nov-19   16:51 )
  Astrazeneca Pharma gains after DGCA approves anti-diabetic drug
 ( Hot Pursuit - 26-Sep-19   10:25 )
Other Stories
  State Bank of India receives affirmation in credit ratings from Moody's
  03-Oct-24   19:15
  Indian Oil signs B2B Framework Agreement with Nepal Oil Corporation
  03-Oct-24   19:06
  Mahindra & Mahindra's Thar ROXX records 1.76 lakh booking within 60 mins
  03-Oct-24   17:14
  Shilpa Medicare announces receipt of CEP from EDQM for API 'Desmopressin'
  03-Oct-24   17:12
  Board of Refex Industries approves fund raising up to Rs 927 cr via equity route
  03-Oct-24   17:05
  Mahindra & Mahindra Financial Services approves NCD issuance of Rs 750 cr
  03-Oct-24   17:02
  Rites signs MoU with Delhi Metro Rail Corporation
  03-Oct-24   16:42
  Scan Projects to convene board meeting
  03-Oct-24   15:58
  Polycab India to announce Quarterly Result
  03-Oct-24   15:58
  Hindustan Organic Chemicals to conduct board meeting
  03-Oct-24   15:58
Back Top